In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...

Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Q4 2024 Management View CEO Albert Bourla highlighted Pfizer's strong execution in 2024, emphasizing the successful integration of Seagen, which has positioned Pfizer as a leading oncology company. He ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Pfizer, a renowned biopharmaceutical company, excels in discovering and developing innovative medicines and vaccines. Its ...

Pfizer Inc. has announced that Jeffrey Legos, PhD, MBA, will join the company as Chief Oncology Officer. In this role, Dr.